Impact of Food and Drink Administration Vehicles on Paediatric Formulation Performance: Part 1-Effects on Solubility of Poorly Soluble Drugs.


Journal

AAPS PharmSciTech
ISSN: 1530-9932
Titre abrégé: AAPS PharmSciTech
Pays: United States
ID NLM: 100960111

Informations de publication

Date de publication:
26 Jun 2020
Historique:
received: 07 05 2020
accepted: 04 06 2020
entrez: 28 6 2020
pubmed: 28 6 2020
medline: 21 10 2020
Statut: epublish

Résumé

Food and drinks are commonly used to facilitate administration of paediatric medicines to improve palatability and enhance patient compliance. However, the impact of this practice on drug solubility and on oral drug bioavailability is not usually studied. Based on recommended strategies for oral administration of paediatric medicines with food and drink vehicles, the aims of this study were (i) to measure the physicochemical properties of (soft) food and drink vehicles, commonly mixed with paediatric medicines prior to administration, and (ii) to assess the impact of the co-administered vehicles on the solubility of two poorly soluble paediatric drugs. Montelukast (sodium) and mesalazine were selected as the model compounds. Distinct differences were observed between the physicochemical properties (i.e. pH, surface tension, osmolality, viscosity and buffer capacity) and macronutrient composition (i.e. fat, sugar and protein content) of the different soft foods and drinks, not only among vehicle type but also within vehicles of the same subtype. Solubility studies of the two model compounds in selected drinks and soft foods resulted in considerably different drug solubility values in each vehicle. The solubility of the drugs was significantly affected by the vehicle physicochemical properties and macronutrient composition, with the solubility of montelukast being driven by the pH, fat and protein content of the vehicles and the solubility of mesalazine by vehicle osmolality, viscosity and sugar content. This vehicle-dependent impact on drug solubility could compromise its bioavailability, and ultimately affect the safety and/or efficacy of the drug and should be taken into consideration during paediatric product development.

Identifiants

pubmed: 32592045
doi: 10.1208/s12249-020-01722-z
pii: 10.1208/s12249-020-01722-z
pmc: PMC7373161
doi:

Substances chimiques

Excipients 0
Pharmaceutical Preparations 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

177

Références

J Automat Chem. 1989;11(2):80-3
pubmed: 18925239
J Clin Oncol. 2016 Apr 20;34(12):1309-14
pubmed: 26858332
J Pharm Pharmacol. 2017 Apr;69(4):384-397
pubmed: 27704550
Pharm Res. 1995 Mar;12(3):413-20
pubmed: 7617530
Mol Pharm. 2010 Oct 4;7(5):1527-32
pubmed: 20726533
Neurogastroenterol Motil. 2007 Nov;19(11):879-86
pubmed: 17973639
J Control Release. 2009 Sep 15;138(3):251-9
pubmed: 19464331
J Am Diet Assoc. 2009 Oct;109(10):1816
pubmed: 19782182
Pharm Res. 1990 May;7(5):537-41
pubmed: 1694991
Eur J Pharm Biopharm. 2001 May;51(3):183-90
pubmed: 11343881
Children (Basel). 2015 Jun 09;2(2):244-71
pubmed: 27417362
Am J Health Syst Pharm. 2004 Jun 1;61(11):1135-42
pubmed: 15237566
J Pharm Sci. 2011 Nov;100(11):4823-35
pubmed: 21766309
Pharm Res. 2004 Sep;21(9):1539-44
pubmed: 15497676
J Gen Physiol. 1919 May 20;1(5):521-4
pubmed: 19871767
J Agric Food Chem. 2004 Feb 25;52(4):948-52
pubmed: 14969555
Food Sci Nutr. 2016 Jul 27;5(2):358-364
pubmed: 28265371
Paediatr Int Child Health. 2015 Feb;35(1):24-8
pubmed: 25034798
J Pharm Pharm Sci. 2014;17(2):207-19
pubmed: 24934549
J Agric Food Chem. 1999 Sep;47(9):3546-50
pubmed: 10552683
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D668-72
pubmed: 16381955
Int J Pharm Pract. 2012 Jun;20(3):191-8
pubmed: 22554162
Clin Ther. 2008 Jul;30(7):1300-8
pubmed: 18691989
Adv Drug Deliv Rev. 2014 Jun;73:2-13
pubmed: 24556465
Pharm Res. 2008 Dec;25(12):2778-85
pubmed: 18560996
J Pharm Sci. 1981 Jan;70(1):22-32
pubmed: 7229926
Eur J Pharm Biopharm. 2015 Nov;97(Pt A):39-50
pubmed: 26391972
Adv Drug Deliv Rev. 2007 Jul 30;59(7):591-602
pubmed: 17599644
J Pharm Pharmacol. 2004 May;56(5):605-10
pubmed: 15142337
Arzneimittelforschung. 1985;35(9):1457-9
pubmed: 2867770
Rocz Panstw Zakl Hig. ;68(2):167-173
pubmed: 28646834
Pediatrics. 2014 Aug;134(2):361-72
pubmed: 25022739
Int J Clin Pharm. 2015 Dec;37(6):1057-67
pubmed: 26173937

Auteurs

J Martir (J)

Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath, BA2 7AY, UK.

T Flanagan (T)

Oral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, UK.
Currently at UCB Pharma, Chemin du Foriest, B-1420, Braine-l'Alleud, Belgium.

J Mann (J)

Oral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, UK.

N Fotaki (N)

Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath, BA2 7AY, UK. n.fotaki@bath.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH